Work

Antiviral target compound profile for pandemic preparedness

Year: 2024

Type: article

Source: Nature Reviews Drug Discovery

DOI: 10.1038/s41573-024-01102-3

Authors: James F. Demarest, Ruxandra Draghia-Akli, Tomas Cihlar, Kenneth Bradley, John A. T. Young, Richa Chandra, Sujata Vaidyanathan, Margaret Chu-Moyer, Christopher L. Lynch, Andrew Campbell, Kumar Singh Saikatendu, John P. Bilello, Yoshihiko Murata, Marnix van Loock, Aeron C. Hurt, Timothy Tellinghuisen, Lee Ruggiero, Richard Mackman, Nina M. Hill, John C. Pottage, on behalf of the INTREPID Alliance, Marnix van Loock

Institutions: Gilead Sciences (United States), F. Hoffmann-La Roche AG, Amgen (United States), AbbVie (United States), Janssen (Belgium)

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4404903860

FWCI: 2.224

Cites: 3

Cited by: 7

Related to: 10